References
- Portman DJ, Gass MLS, Kingsberg S, et al. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and The North American Menopause Society. J Sex Med 2014;11:2865–72.
- Nappi RE, Palacios S, Panay N, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric 2016;19:188–97.
- Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87–94.
- Management of symptomatic vulvovaginal atrophy. Menopause 2013;20:888–902.
- DiBonaventura M, Luo X, Moffatt M, et al. The Association between Vulvovaginal Atrophy Symptoms and Quality of Life among postmenopausal women in the United States and Western Europe. J Womens Health (Larchmt) 2015;24:713–22.
- Goldstein SR, Bachmann GA, Koninckx PR, et al.; Ospemifene Study Group the OS. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014;17:173–82.
- Pinkerton J, Stanczyk F. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. Menopause (New York, NY) 2014;21:309–19.
- Degregorio MW, Zerbe RL, Wurz GT. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids 2014;90:82–93.
- Liang R, Knight K, Nolfi A, et al. Differential effects of selective estrogen receptor modulators on the vagina and its supportive tissues. Menopause 2016;23:129–37.
- Eigeliene N, Kangas L, Hellmer C, et al. Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Menopause 2016;23:719–30.
- Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women. Menopause 2009;17:1.
- Portman D, Palacios S, Nappi RE, et al. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 2014;78:91–8.
- Rutanen E-M, Heikkinen J, Halonen K, et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 2003;10:433–9.
- Practice Bulletin No. 168 summary. Obstet Gynecol 2016;128:923–5.
- Bachmann G. Urogenital ageing: an old problem newly recognized. Maturitas 1995;22:S1–S5.
- Baldassarre M, Alvisi S, Berra M, et al. Changes in vaginal physiology of menopausal women with type 2 diabetes. J Sex Med 2015;12:1346–55.
- Rahn DD, Ward RM, Sanses TV, et al. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int Urogynecol J 2015;26:3–13.
- Bruyniks N, Nappi RE, Castelo-Branco C, et al. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric 2016;19:60–5.
- Constantine G, Graham S, Koltun WD, et al. Assessment of ospemifene or lubricants on clinical signs of VVA. J Sex Med 2014;11:1033–41.
- Nappi RE, Panay N, Bruyniks N, et al. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 2015;18:233–40.
- Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 2015;18:226–32.
- Portman DJ, Bachmann G, Simon J. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623–30.
- Unkila M, Kari S, Yatkin E, et al. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause. J Steroid Biochem Mol Biol 2013;138:107–15.